This project provided the client with a compliant, scalable CPV model that strengthened process control and enabled earlier detection of variability—setting a benchmark for future validation activities
About this Case Study
In this case study, we explore how Rephine supported a pharmaceutical manufacturing site facing internal resource constraints and lacking the expertise to initiate a Continued Process Verification (CPV) programme for one of its most critical processes.
Rephine’s consultants designed a tailored CPV policy aligned with GMP guidelines and regulatory expectations. The solution enabled the site to:
- Define key process parameters (CPPs) and critical quality attributes (CQAs)
- Establish appropriate control limits and statistical tools
- Evaluate performance using capability indices (Cp, Cpk)
- Prepare a regulator-ready CPV report
Over a six-month period, Rephine helped the client move from uncertainty to full implementation—delivering not just compliance, but enhanced decision-making and a scalable model for future products.
Download the full case study now to see how we translated CPV theory into measurable operational gains.
Download the Case Study
View other our other resources and company news
Guide Practical Guide to Post-Market Surveillance (PMS) under EU MDR/IVDR
Blog AI for Pharmaceutical SOPs: Transforming Quality Management and Compliance
CAPA Strengthening CAPA & Exceptions Management
Blog EU GMP Annex 1 vs FDA Aseptic Guide: Bridging Compliance
Blog GMP & GDP: Ensuring Quality in Drug Storage and Transport
Blog Blockchain for GMP Documentation: Hype or Future Reality?
Guide Is Your Insurance Policy Ready for the New EU Product Liability Directive?
Article 100% Drug Tariffs in the U.S. – Impact on Pharma Supply Chains & Compliance
Blog 